Gil Blum
Stock Analyst at Needham
(4.64)
# 808
Out of 4,978 analysts
712
Total ratings
43.1%
Success rate
13.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gil Blum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Upgraded: Buy | $9 | $3.48 | +158.62% | 51 | Sep 16, 2026 | |
| LYEL Lyell Immunopharma | Reiterated: Buy | $44 | $10.78 | +308.35% | 7 | Sep 11, 2026 | |
| TCRX TScan Therapeutics | Downgraded: Hold | n/a | $0.331 | - | 19 | Sep 2, 2026 | |
| CRSP CRISPR Therapeutics AG | Reiterated: Buy | $82 | $52.21 | +57.06% | 43 | Aug 31, 2026 | |
| FTH Faeth Therapeutics | Initiated Coverage: Buy | $56 | $34.24 | +63.55% | 1 | Aug 21, 2026 | |
| CELC Celcuity | Rated: Buy | $157 → $140 | $82.58 | +69.53% | 34 | Aug 14, 2026 | |
| FATE Fate Therapeutics | Reiterated: Hold | n/a | $2.44 | - | 24 | Aug 13, 2026 | |
| ABSI Absci | Reiterated: Buy | $11 | $8.04 | +36.82% | 14 | Aug 12, 2026 | |
| TSHA Taysha Gene Therapies | Reiterated: Buy | $12 | $5.07 | +136.69% | 50 | Aug 12, 2026 | |
| AUTL Autolus Therapeutics | Reiterated: Buy | $10 | $1.87 | +434.76% | 52 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 | $0.266 | +1,027.82% | 35 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $2.87 | +283.28% | 23 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 | $11.92 | +76.17% | 2 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $41 | $8.60 | +376.74% | 16 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $8.72 | +117.89% | 8 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 | $31.62 | +137.23% | 23 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $7.91 | +405.69% | 37 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | n/a | $19.76 | - | 56 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $1.29 | +210.08% | 36 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $3.19 | +150.78% | 30 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 | $25.15 | +35.19% | 48 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $5.88 | - | 28 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.57 | - | 25 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $6.03 | n/a | 15 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $27.91 | n/a | 14 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $91.17 | n/a | 10 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.000001 | n/a | 6 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $0.0001 | n/a | 5 | Apr 6, 2022 |
Rocket Pharmaceuticals
Sep 16, 2026
Upgraded: Buy
Price Target: $9
Current: $3.48
Upside: +158.62%
Lyell Immunopharma
Sep 11, 2026
Reiterated: Buy
Price Target: $44
Current: $10.78
Upside: +308.35%
TScan Therapeutics
Sep 2, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.331
Upside: -
CRISPR Therapeutics AG
Aug 31, 2026
Reiterated: Buy
Price Target: $82
Current: $52.21
Upside: +57.06%
Faeth Therapeutics
Aug 21, 2026
Initiated Coverage: Buy
Price Target: $56
Current: $34.24
Upside: +63.55%
Celcuity
Aug 14, 2026
Rated: Buy
Price Target: $157 → $140
Current: $82.58
Upside: +69.53%
Fate Therapeutics
Aug 13, 2026
Reiterated: Hold
Price Target: n/a
Current: $2.44
Upside: -
Absci
Aug 12, 2026
Reiterated: Buy
Price Target: $11
Current: $8.04
Upside: +36.82%
Taysha Gene Therapies
Aug 12, 2026
Reiterated: Buy
Price Target: $12
Current: $5.07
Upside: +136.69%
Autolus Therapeutics
Aug 11, 2026
Reiterated: Buy
Price Target: $10
Current: $1.87
Upside: +434.76%
Aug 11, 2026
Reiterated: Buy
Price Target: $3
Current: $0.266
Upside: +1,027.82%
Aug 11, 2026
Reiterated: Buy
Price Target: $11
Current: $2.87
Upside: +283.28%
Aug 10, 2026
Reiterated: Buy
Price Target: $21
Current: $11.92
Upside: +76.17%
Aug 7, 2026
Reiterated: Buy
Price Target: $41
Current: $8.60
Upside: +376.74%
Aug 7, 2026
Reiterated: Buy
Price Target: $19
Current: $8.72
Upside: +117.89%
Aug 6, 2026
Reiterated: Buy
Price Target: $75
Current: $31.62
Upside: +137.23%
Aug 6, 2026
Reiterated: Buy
Price Target: $40
Current: $7.91
Upside: +405.69%
Aug 6, 2026
Reiterated: Sell
Price Target: n/a
Current: $19.76
Upside: -
Aug 5, 2026
Reiterated: Buy
Price Target: $4
Current: $1.29
Upside: +210.08%
Aug 5, 2026
Reiterated: Buy
Price Target: $8
Current: $3.19
Upside: +150.78%
Aug 4, 2026
Reiterated: Buy
Price Target: $34
Current: $25.15
Upside: +35.19%
Nov 7, 2025
Reiterated: Hold
Price Target: n/a
Current: $5.88
Upside: -
Oct 24, 2025
Rated: Hold
Price Target: n/a
Current: $1.57
Upside: -
Dec 27, 2024
Rated: Hold
Price Target: n/a
Current: $6.03
Upside: n/a
Dec 7, 2022
Reiterated: Buy
Price Target: $6
Current: $27.91
Upside: n/a
Aug 25, 2022
Rated: Hold
Price Target: n/a
Current: $91.17
Upside: n/a
Jun 3, 2022
Rated: Hold
Price Target: n/a
Current: $0.000001
Upside: n/a
Apr 6, 2022
Reiterated: Buy
Price Target: $6
Current: $0.0001
Upside: n/a